Alzheimer's Disease Metal Chelation and Antioxidant Therapy Companies

Overview

Overview

This category covers biotechnology and pharmaceutical companies developing therapies targeting metal dyshomeostasis and oxidative stress in Alzheimer's disease. These approaches address two interconnected pathological features that are increasingly recognized as central drivers of neurodegeneration: the disruption of copper, zinc, and iron homeostasis in the brain, and the consequent generation of reactive oxygen species that damage neurons, proteins, and cellular structures.

Metal dyshomeostasis is one of the earliest detectable abnormalities in Alzheimer's disease, often preceding clinical symptoms by decades. Elevated iron accumulates in specific brain regions, copper homeostasis becomes disrupted, and zinc signaling is altered. These metal abnormalities contribute to amyloid-beta aggregation, tau phosphorylation, oxidative stress generation, and neuroinflammation. Simultaneously, the aging brain faces declining antioxidant capacity, leading to a vicious cycle of oxidative damage and neuronal dysfunction["@metal_ad_review"][@oxidative_ad].

Companies in this space pursue diverse mechanisms including direct metal chelation, antioxidant therapies, metal homeostasis modulation, and metabolic approaches that indirectly reduce oxidative stress. Unlike traditional approaches focused solely on amyloid or tau, these therapies aim to correct fundamental cellular dysfunctions that underlie multiple pathological features of AD.

Key Companies

Metal Homeostasis Modulation

Aleza Therapeutics

• Focus: TREM2 activation and copper/zinc homeostasis modulation
• Lead Candidate: AZT-101 (TREM2 agonist)
• Indication: Early Alzheimer's disease
• Stage: Phase IIa
• Mechanism: TREM2 agonism enhances microglial phagocytosis and modulates metal ion handling in the brain
• Notes: Oral small molecule approach differentiating from antibody therapies; addresses both amyloid clearance and neuroinflammation through microglial modulation
• Page: [Aleza Therapeutics](/companies/aleza-therapeutics)

Vivoryon Therapeutics N.V.

• Focus: Glutaminyl cyclase inhibition
• Lead Candidate: Varoglutamstat (PQ912)
• Indication: Early Alzheimer's disease
• Stage: Phase IIb (VIVIAD)
• Mechanism: Inhibits glutaminyl cyclase (QC) to prevent formation of pGlu-modified amyloid-beta, which exhibits enhanced metal-binding and aggregation properties
• Notes: Unique mechanism targeting N-terminal pyroglutamate modification that increases Aβ metal affinity and neurotoxicity; demonstrated target engagement in Phase IIa (SAPIR trial)
• Page: [Vivoryon Therapeutics](/companies/vivoryon)

T3D Therapeutics

• Focus: PPAR delta/gamma dual agonism targeting metabolic dysfunction
• Lead Candidate: T3D-959
• Indication: Alzheimer's disease
• Stage: Phase 2 (PIONEER trial)
• Mechanism: Dual PPAR activation improves brain glucose metabolism, reduces neuroinflammation, and indirectly reduces oxidative stress through improved mitochondrial function
• Notes: First-in-class oral small molecule; addresses brain metabolic dysfunction which contributes to metal dyshomeostasis and oxidative stress
• Page: [T3D Therapeutics](/companies/t3d-therapeutics)

Iron Chelation Approaches

Apopharma Inc.

• Focus: Iron chelation therapy
• Lead Candidate: Deferiprone
• Indication: Alzheimer's disease (exploratory)
• Stage: Research/Preclinical
• Mechanism: Oral iron chelator that can cross the blood-brain barrier and reduce brain iron stores
• Notes: Primarily focused on Parkinson's disease (FAIRPARK trials); investigating applicability to AD where iron accumulation also occurs
• Page: [Apopharma Inc.](/companies/apopharma)

Antioxidant and Mitochondrial Protection

MitoThera

• Focus: Mitochondria-targeted antioxidants
• Lead Candidate: MT-101
• Indication: Alzheimer's disease (exploratory)
• Stage: Discovery
• Mechanism: Uses triphenylphosphonium (TPP) cation to deliver antioxidants directly to mitochondrial matrix; catalytically regenerated by electron transport chain
• Notes: Primarily focused on Parkinson's disease; mitochondrial oxidative stress is a shared feature in AD
• Page: [MitoThera](/companies/mitothera)

Additional Companies in Related Space

| Company | Focus | Mechanism | Stage | Notes |
|---------|-------|-----------|-------|-------|
| Alterity Therapeutics | Protein aggregation with metal-binding | Quinazolinone small molecules with metal interaction | Phase 1 (PD) | Originally developed PBT2 for AD; shifted to PD focus |
| Nobelpharma | Rare neurological diseases | Various mechanisms | Multiple | Japanese company focused on orphan neurological conditions |

Therapeutic Mechanisms

Metal Chelation Approaches

Antioxidant Approaches

Metabolic Approaches

Scientific Rationale

Metal Dyshomeostasis in AD

The role of metal dyshomeostasis in Alzheimer's disease is supported by multiple lines of evidence:

Iron Dysregulation:

• Increased iron in specific brain regions (hippocampus, basal ganglia) as early as MCI
• Ferritin elevation in CSF correlates with disease progression
• Iron promotes amyloid-beta aggregation through Fenton chemistry
• Iron accumulation in microglia correlates with disease severity[@metal_ad_review]

• Serum copper alterations in AD patients
• Copper interacts with amyloid-beta to form toxic complexes
• Ceruloplasmin abnormalities in AD
• Copper deficiency in brain despite systemic accumulation[@copper_zinc_ad]

• Altered zinc transporter expression in AD brain
• Zinc modulates amyloid-beta aggregation
• Zinc deficiency affects synaptic function
• Zinc supplementation trials show mixed results

Oxidative Stress in AD

Oxidative damage is one of the earliest detectable features of AD:

• Increased lipid peroxidation markers (4-HNE, MDA)
• Protein oxidation (carbonylated proteins)
• DNA oxidation (8-OHdG)
• Mitochondrial DNA mutations accumulate
• Antioxidant systems decline with age and in AD[@oxidative_ad]

Pipeline Summary

| Company | Drug | Mechanism | Phase | Indication |
|---------|------|-----------|-------|-------------|
| Aleza Therapeutics | AZT-101 | TREM2 agonist/copper-zinc modulation | Phase IIa | Early AD |
| Vivoryon | Varoglutamstat | QC inhibitor | Phase IIb | Early AD |
| T3D Therapeutics | T3D-959 | PPAR δ/γ agonist | Phase 2 | AD |
| Apopharma | Deferiprone | Iron chelation | Research | AD |
| MitoThera | MT-101 | Mitochondria-targeted antioxidant | Discovery | AD |

Clinical Development Considerations

Biomarkers for Patient Selection

Key biomarkers being developed to enrich patient populations:

• Iron markers: Serum ferritin, CSF ferritin, MRI R2*
• Copper markers: Serum copper, ceruloplasmin activity
• Oxidative stress markers: 8-OHdG, isoprostanes, 4-HNE
• Amyloid/tau status: PET imaging, CSF Aβ42/40, p-tau

Challenges in the Field

Research Context

Metal-Based Therapeutic Strategies

The therapeutic rationale for metal-targeting approaches in AD:

Antioxidant Therapy Rationale

Antioxidant approaches aim to:

Cross-Links

• [Metal Dyshomeostasis in AD](/mechanisms/metal-dyshomeostasis)
• [Oxidative Stress in AD](/mechanisms/oxidative-stress-pathway)
• [Copper and Zinc in Neurodegeneration](/mechanisms/metal-homeostasis-neurodegeneration)
• [Iron Accumulation in Neurodegeneration](/mechanisms/iron-dysregulation)
• [Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction)
• [AD Mitochondria-Targeting Companies](/companies/ad-mitochondria-targeting-companies)
• [AD Neuroinflammation Companies](/companies/ad-neuroinflammation-companies)
• [AD Pipeline Companies](/companies/ad-pipeline-companies)

References